8-KMaterial AgreementsExhibits & Filings

JOHNSON & JOHNSON 8-K Report, Material Agreement (Feb 1, 2017)

Filed February 1, 2017For Securities:JNJ

Summary

Johnson & Johnson (JNJ) has entered into a definitive agreement to acquire Actelion Ltd. through an all-cash tender offer for USD280 per share. This significant transaction involves a two-part structure: JNJ will acquire Actelion's marketed products and late-stage clinical development assets, while Actelion's drug discovery operations and early-stage assets will be spun off into a new, publicly traded Swiss biopharmaceutical company, R&D NewCo. This demerger will occur immediately prior to the acquisition, with Actelion shareholders receiving shares in R&D NewCo as a dividend in kind. This strategic move signals JNJ's intent to bolster its pharmaceutical pipeline, particularly in areas with high growth potential. The acquisition of Actelion's established products and promising early-stage assets, combined with the creation of R&D NewCo to house the more speculative research, allows JNJ to access innovative therapies while mitigating some of the inherent risks associated with early-stage drug development. The deal is subject to customary closing conditions, including regulatory approvals and a high tender acceptance rate from Actelion shareholders.

Key Highlights

  • 1Johnson & Johnson to acquire Actelion Ltd. for USD280 per share in an all-cash tender offer.
  • 2Transaction involves a demerger of Actelion's early-stage R&D assets into a new independent company (R&D NewCo).
  • 3Actelion shareholders will receive shares in R&D NewCo as a dividend in kind before the acquisition.
  • 4R&D NewCo will be listed on the SIX Swiss Exchange and will receive significant funding, including a convertible note facility from a JNJ affiliate.
  • 5JNJ's pharmaceutical segment is expected to be enhanced by Actelion's marketed products and late-stage pipeline.
  • 6The deal includes customary closing conditions, such as regulatory approvals and a minimum tender threshold of two-thirds of Actelion shares.
  • 7JNJ secures an option on ACT-132577, a resistant hypertension drug candidate within R&D NewCo, through a collaboration agreement.

Frequently Asked Questions

The filing states the offer price is USD280 per share for all outstanding, publicly held shares of Actelion. The total value would depend on the total number of outstanding shares, which is not specified in this 8-K filing but would be detailed in subsequent filings and regulatory disclosures.

R&D NewCo is a newly created Swiss biopharmaceutical company that will comprise Actelion's drug discovery operations and early-stage clinical development assets. It will be spun off from Actelion and listed on the SIX Swiss Exchange, and its shares will be distributed to Actelion shareholders immediately prior to Johnson & Johnson's acquisition of the remaining Actelion business.

The consummation of the offer is subject to several customary closing conditions, including the tender of more than two-thirds of Actelion's shares, clearance by relevant merger control authorities, the absence of a material adverse effect on Actelion, and approval by Actelion shareholders of the R&D NewCo distribution.

While not explicitly detailed in this 8-K, the acquisition of Actelion, particularly its marketed products and late-stage pipeline, along with early-stage assets housed in R&D NewCo, suggests a strategy to enhance Johnson & Johnson's pharmaceutical portfolio and R&D capabilities, especially in potentially high-growth therapeutic areas.